Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial

IMPORTANCE: Doses of fingolimod lower than 0.5 mg per day were not investigated during the fingolimod clinical development program. Whether lower doses of fingolimod might retain efficacy with fewer safety risks remains unknown. OBJECTIVE: To evaluate the efficacy and safety of fingolimod, 0.5 mg, a...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:JAMA Neurol
Main Authors: Cree, Bruce A. C., Goldman, Myla D., Corboy, John R., Singer, Barry A., Fox, Edward J., Arnold, Douglas L., Ford, Corey, Weinstock-Guttman, Bianca, Bar-Or, Amit, Mientus, Susanne, Sienkiewicz, Daniel, Zhang, Ying, Karan, Rajesh, Tenenbaum, Nadia
פורמט: Artigo
שפה:Inglês
יצא לאור: American Medical Association 2021
נושאים:
Original Investigation
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC7445630/
https://ncbi.nlm.nih.gov/pubmed/32852530
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaneurol.2020.2950
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים